Clinical translation of novel human pluripotent stem cell (hPSC)-based therapies for
a wide range of diseases will require robust, scalable bioreactor technologies to
manufacturing large quantities of therapeutic cells. While mouse PSC yields in bioreactors
are comparable to traditional adherent culture (>50 fold expansion over 4 days), translation
of hPSCs to suspension yields only 3–6 fold expansion over 7 days. We hypothesize
that this discrepancy results from a cell state difference: mouse PSCs exist in an
earlier developmental “naïve” state which has enhanced bioprocessing properties relative
to the later “primed” state in which hPSCs exist.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
